2024
Vitamin B12 Supplementation in Psychiatric Practice
Kennedy K, Alexander J, Garakani A, Gross L, Mintz D, Parikh T, Pine J, Sumner C, Baron D. Vitamin B12 Supplementation in Psychiatric Practice. Current Psychiatry Reports 2024, 26: 265-272. PMID: 38696105, DOI: 10.1007/s11920-024-01505-4.Peer-Reviewed Original ResearchPsychiatric disordersB12 deficiencyB12 supplementationPsychiatric symptomsB12 levelsPharmacological treatment of psychiatric disordersTreatment of psychiatric disordersRisk factorsAssociated with neuropsychiatric symptomsSevere psychiatric presentationsManifestations of B12 deficiencyMild depressive symptomsVitamin B12 supplementationDepressive symptomsPsychiatric practicePsychiatric presentationsMedical workupNeuropsychiatric symptomsSymptoms of B12 deficiencyAugmentation strategiesPrevent depressionPharmacological treatmentCardinal symptomsDisordersSymptomsLifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP)
Hooshyari Z, Mohammadi M, Salmanian M, Ahmadi N, Khaleghi A, Garakani A. Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP). European Child & Adolescent Psychiatry 2024, 1-14. PMID: 38656607, DOI: 10.1007/s00787-024-02441-7.Peer-Reviewed Original ResearchPrevalence of post-traumatic stress disorderPost-traumatic stress disorderTraumatic eventsAnxiety disordersStress disorderPsychiatric disordersSchool-Age Children-Present and Lifetime VersionKiddie Schedule for Affective DisordersSchedule for Affective DisordersLifetime prevalenceLifetime prevalence of post-traumatic stress disorderType of traumatic eventPredictors of post-traumatic stress disorderRates of PTSDSeparation anxiety disorderGeneralized anxiety disorderK-SADS-PLOppositional defiant disorderPrevalence of PTSDRates of comorbidityAdolescent psychiatric disordersLifetime prevalence ratesPrevalence rates of comorbiditiesDepressive disorderLifetime VersionAntipsychotic agents in anxiety disorders: An umbrella review
Garakani A, Buono F, Salehi M, Funaro M, Klimowicz A, Sharma H, Faria C, Larkin K, Freire R. Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatrica Scandinavica 2024, 149: 295-312. PMID: 38382649, DOI: 10.1111/acps.13669.Peer-Reviewed Original ResearchSecond-generation antipsychoticsFirst-generation antipsychoticsGeneralized anxiety disorderStudies of antipsychoticsAnxiety disordersAntipsychotic agentsEfficacy of first-generation antipsychoticsTreatment of anxiety disordersEfficacy of antipsychotic agentsMeta-analysesAntidepressant treatmentNonantipsychotic medicationsAntipsychoticsFirst-line treatmentAnxietyComparing monotherapyUmbrella reviewDisordersQuetiapineSystematic reviewSide effectsAMSTAR-2Off-labelAPA PsycInfoCINAHL Complete
2023
Editorial: Assessing and evaluating the impact of the COVID-19 pandemic on anxiety and stress: perspectives from North America
Salehi M, Amanat M, Garakani A. Editorial: Assessing and evaluating the impact of the COVID-19 pandemic on anxiety and stress: perspectives from North America. Frontiers In Psychiatry 2023, 14: 1275415. PMID: 37953933, PMCID: PMC10635498, DOI: 10.3389/fpsyt.2023.1275415.Commentaries, Editorials and LettersSubstance Use in Athletes
Dougherty J, Garakani A, Thom R. Substance Use in Athletes. 2023, 211-228. DOI: 10.1007/978-3-031-36864-6_14.ChaptersPsychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani A, Alexander J, Sumner C, Pine J, Gross L, Raison C, Aaronson S, Baron D. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal Of Psychiatric Practice 2023, 29: 345-353. PMID: 37678363, DOI: 10.1097/pra.0000000000000729.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCommentary: Mania in Medically Ill Patients
Garakani A. Commentary: Mania in Medically Ill Patients. Journal Of Psychiatric Practice 2023, 29: 426-427. PMID: 37678372, DOI: 10.1097/pra.0000000000000731.Commentaries, Editorials and LettersConceptsBipolar disorderBehçet's diseasePatient's symptomsManic symptomsMedical settingsMedically Ill PatientsComprehensive medical evaluationPrimary bipolar disorderSecondary maniaIll patientsMedical illnessMedical floorPsychiatric providersCase reportThorough historyEmergency roomEmergency settingMedical evaluationPsychiatric consultationPsychiatric treatmentPatientsFrontal lobeSymptomsDiseaseDisordersDisparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation
Sprong M, Hollender H, Lee Y, Williams L, Sneed Z, Garakani A, Buono F. Disparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation. Frontiers In Psychiatry 2023, 14: 1200450. PMID: 37520235, PMCID: PMC10382058, DOI: 10.3389/fpsyt.2023.1200450.Peer-Reviewed Original ResearchActive alcohol use disorderSubstance use disordersUse disordersVeterans Health Administration medical centersCo-occurring substance use disordersVocational rehabilitationProgram enrollmentCo-occurring alcoholCo-occurring depressionDiagnosis of anxietyCo-occurring diagnosesAlcohol use disorderPost-traumatic stress disorderInstitutional review boardVeteran patientsMedical CenterPsychiatric diagnosisCurrent studyBipolar disorderRehabilitation servicesReview boardStress disorderEffective interventionsAnxiety diagnosesDiagnosisImpact of Substance Use Disorders on Employment for Veterans
Sprong ME, Hollender H, Paul E, Gilbert J, Weber K, Garakani A, Buono FD. Impact of Substance Use Disorders on Employment for Veterans. Psychological Services 2023, 20: 222-231. PMID: 35849362, DOI: 10.1037/ser0000690.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersImpact of SUDMental health conditionsSerious mental health conditionsVocational rehabilitation programCommunity-based employmentMedical conditionsRehabilitation programAlcohol useHealth conditionsVeteransIllicit drugsVR programClosure statusDisordersPresent studyFindingsTransitional work
2022
Commentary: Psychiatric Symptoms Related to Somatic Illness
Garakani A. Commentary: Psychiatric Symptoms Related to Somatic Illness. Journal Of Psychiatric Practice 2022, 28: 514-515. PMID: 36355593, DOI: 10.1097/pra.0000000000000674.Commentaries, Editorials and LettersConceptsAuditory hallucinationsVisual hallucinationsPsychiatric historySomatic illnessPatient's psychiatric historySemicircular canal dehiscencePsychosis presentPsychiatric consultation serviceCharles Bonnet syndromeCanal dehiscenceHypertensive episodesCases of hallucinationsPsychiatric symptomsPsychotic symptomsPsychotic disordersProper diagnosisMedical providersPatientsMedical teamSymptomsConsultation serviceHallucinationsThought disorderIllnessDisordersCommentary: Futility in Psychiatry
Garakani A. Commentary: Futility in Psychiatry. Journal Of Psychiatric Practice 2022, 28: 349-350. PMID: 35797694, DOI: 10.1097/pra.0000000000000649.Commentaries, Editorials and LettersAn umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorderCommentary: Diagnostic Challenges
Garakani A. Commentary: Diagnostic Challenges. Journal Of Psychiatric Practice 2022, 28: 270-271. PMID: 35511106, DOI: 10.1097/pra.0000000000000630.Commentaries, Editorials and LettersAn exploratory study of anxiety-motivated gambling in adolescents: Associations with minority status and gambling, health and functioning measures
Cardwell E, Hoff RA, Garakani A, Krishnan-Sarin S, Potenza MN, Zhai ZW. An exploratory study of anxiety-motivated gambling in adolescents: Associations with minority status and gambling, health and functioning measures. Journal Of Psychiatric Research 2022, 151: 445-453. PMID: 35598502, PMCID: PMC9204846, DOI: 10.1016/j.jpsychires.2022.03.052.Peer-Reviewed Original ResearchConceptsProblem gamblingGambling-related measuresRisk/problem gamblingNon-strategic gamblingEmotion dysregulationEmotional dysregulationHealth/functioningHigh school studentsBehavioral correlatesGroup differencesConnecticut high school studentsGamblingRisky behaviorsAnxietyAdolescentsPermissive attitudesFeeling pressureGambling perceptionsMinority statusMotivationExploratory studyDrug useSpecific factorsMinority groupsMeasuresDevelopment and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5)
Garakani A, Buono FD, Larkin K, Polonsky M, Goldberg JF. Development and validation of a new scale to measure chronic suicidal ideation: The Chronic Suicidal Ideation Inventory-5 (CSI-5). Journal Of Psychiatric Research 2022, 150: 160-164. PMID: 35385817, DOI: 10.1016/j.jpsychires.2022.03.021.Peer-Reviewed Original ResearchConceptsChronic suicidal ideationSuicidal ideationSuicidal thoughtsMood disordersNovel self-report instrumentCronbach's alphaDepression severity scoresYale-Brown ObsessiveIndex hospitalizationInpatient cohortMcDonald's omegaPast suicide attemptsSeverity scoreActivity interferenceSuicide attemptsSuicidal thinkingCompulsive ScaleSelf-report instrumentOne-factor solutionIdeationSignificant Pearson correlationScoresCohortInternal consistencyAlpha
2021
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine
Garakani A. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. Journal Of Psychiatric Practice 2021, 27: 496-497. PMID: 34768276, DOI: 10.1097/pra.0000000000000593.Commentaries, Editorials and LettersConceptsTreatment-resistant depressionElectroconvulsive therapyLiver transplantationChronic treatment-resistant depressionUse of ECTMaintenance electroconvulsive therapyMajor depressive episodeBitemporal treatmentsIntranasal formsIntranasal ketaminePartial responsePrescribed antipsychoticsAdjunctive treatmentAntirejection medicationsChronic migraineMigraine medicationsECT treatmentComorbid migraineDepressive episodePsychotic featuresOrgan transplantationKetamine abuseBrain stimulationClinical considerationsPatientsSelective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequencesGuest Editorial: Going Back to My Country
Garakani A. Guest Editorial: Going Back to My Country. Journal Of Psychiatric Practice 2021, 27: 343-345. PMID: 34529600, DOI: 10.1097/pra.0000000000000571.Commentaries, Editorials and LettersCommentary: Psychiatric Presentations of Nonpsychiatric Illness or Treatment
Garakani A. Commentary: Psychiatric Presentations of Nonpsychiatric Illness or Treatment. Journal Of Psychiatric Practice 2021, 27: 404-405. PMID: 34529609, DOI: 10.1097/pra.0000000000000577.Commentaries, Editorials and LettersConceptsManic symptomsPsychiatric historyPerinatal brain injuryOff-label useExamples of patientsPsychogenic nauseaRefractory nauseaGastroesophageal refluxAtypical presentationMood stabilizersSubdural hematomaCertain patientsMedical historyPsychiatric presentationsBrain injuryVisual hallucinationsMedical disordersPsychiatric symptomsPatientsNonpsychiatric illnessCognitive deficitsSuicidal thinkingSymptomsTraditional treatmentBrain imagingIntensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders
Buono FD, Larkin K, Rowe D, Perez-Rodriguez MM, Sprong ME, Garakani A. Intensive Dialectical Behavior Treatment for Individuals With Borderline Personality Disorder With and Without Substance Use Disorders. Frontiers In Psychology 2021, 12: 629842. PMID: 34497550, PMCID: PMC8419465, DOI: 10.3389/fpsyg.2021.629842.Peer-Reviewed Original ResearchSubstance use disordersBorderline personality disorderComorbid substance use disorderUse disordersDialectical behavioral therapyTreatment programComorbid borderline personality disorderPersonality disorderDepression symptom scaleModerate depression scoresDepressive symptomsGroup 2Depression scoresGroup 1Symptom ScaleDBT treatmentSymptom overlapUnivariate general linear modelBehavioral therapyDisordersSignificant decreaseBehavior treatmentGeneral linear modelSignificant differencesPatients